6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) Hexanol: a Promising New Anticancer Compound

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2018 Jan 24

PMID 29358310

Citations 11

Authors

Huan-Huan Sha

Zhen Wang

Shu-Chen Dong

Tian-Mu Hu

Si-Wen Liu

Jun-Ying Zhang

Yang Wu

Rong Ma

Jian-Zhong Wu

Dan Chen

Ji-Feng Feng

Affiliations

Soon will be listed here.

Abstract

The 7-nitro-2,1,3-nitrobenzoxadiazole (NBD) derivatives are a series of compounds containing the NBD scaffold that are not glutathione (GSH) peptidomimetics, and result in a strong inhibition of glutathione S-transferases (GSTs). Growing evidences highlight their pivotal roles and outstanding anticancer activity in different tumor models. In particular, 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol (NBDHEX) is extensively studied, which is a very efficient inhibitor of GSTP1-1. It triggers apoptosis in several tumor cell lines and this cytotoxic activity is observed at micro and submicromolar concentrations. Importantly, studies have shown that NBDHEX acts as an anticancer drug by inhibiting GSTs catalytic activity, avoiding inconvenience of the inhibitor extrusion from the cell by specific pumps and disrupting the interaction between the GSTP1-1 and key signaling effectors. Additionally, some researchers also have discovered that NBDHEX can act as late-phase autophagy inhibitor, which opens new opportunities to fully exploit its therapeutic potential. In this review, we summarize the advantages, anticancer mechanisms, and analogs of this compound, which will establish the basis on the usage of NBDHEX in clinical applications in future.

Citing Articles

Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications.

Lv N, Huang C, Huang H, Dong Z, Chen X, Lu C Antioxidants (Basel). 2023; 12(11).

PMID: 38001822 PMC: 10668987. DOI: 10.3390/antiox12111970.

A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch.

Sun Y, He Q, Li J, Yang Z, Ahmad M, Lin Y Cell Death Dis. 2023; 14(7):463.

PMID: 37491277 PMC: 10368634. DOI: 10.1038/s41419-023-05998-4.

Inhibition Analysis and High-Resolution Crystal Structure of Glutathione Transferase P1-1.

Kupreienko O, Pouliou F, Konstandinidis K, Axarli I, Douni E, Papageorgiou A Biomolecules. 2023; 13(4).

PMID: 37189361 PMC: 10136361. DOI: 10.3390/biom13040613.

Monocarbonyl Curcumin Analogues as Potent Inhibitors against Human Glutathione Transferase P1-1.

Pantiora P, Furlan V, Matiadis D, Mavroidi B, Perperopoulou F, Papageorgiou A Antioxidants (Basel). 2023; 12(1).

PMID: 36670925 PMC: 9854774. DOI: 10.3390/antiox12010063.

The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review.

Tippett V, Tattersall L, Ab Latif N, Shah K, Lawson M, Gartland A Oncogene. 2022; 42(4):259-277.

PMID: 36434179 PMC: 9859755. DOI: 10.1038/s41388-022-02529-x.

References

Pellizzari Tregno F, Sau A, Pezzola S, Geroni C, Lapenta C, Spada M . In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma. Eur J Cancer. 2009; 45(14):2606-17. DOI: 10.1016/j.ejca.2009.06.033. View

Tentori L, Dorio A, Mazzon E, Muzi A, Sau A, Cuzzocrea S . The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. Eur J Cancer. 2011; 47(8):1219-30. DOI: 10.1016/j.ejca.2010.12.008. View

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M . A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Biochem Pharmacol. 2015; 95(1):16-27. DOI: 10.1016/j.bcp.2015.03.004. View

Battisti S, Valente D, Albonici L, Bei R, Modesti A, Palumbo C . Nutritional stress and arginine auxotrophy confer high sensitivity to chloroquine toxicity in mesothelioma cells. Am J Respir Cell Mol Biol. 2011; 46(4):498-506. DOI: 10.1165/rcmb.2011-0195OC. View

Ling V . Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997; 40 Suppl:S3-8. DOI: 10.1007/s002800051053. View

Pasello M, Michelacci F, Scionti I, Hattinger C, Zuntini M, Caccuri A . Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res. 2008; 68(16):6661-8. DOI: 10.1158/0008-5472.CAN-07-5840. View

Borst P . Multidrug resistant proteins. Semin Cancer Biol. 1997; 8(3):131-4. DOI: 10.1006/scbi.1997.0072. View

Inoue T, Ishida T, Sugio K, Maehara Y, Sugimachi K . Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration. 1995; 62(4):223-7. DOI: 10.1159/000196451. View

De Luca A, Rotili D, Carpanese D, Lenoci A, Calderan L, Scimeca M . A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts. Oncotarget. 2015; 6(6):4126-43. PMC: 4414177. DOI: 10.18632/oncotarget.2798. View

10.

Singh S . Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother Pharmacol. 2014; 75(1):1-15. DOI: 10.1007/s00280-014-2566-x. View

11.

Federici L, Sterzo C, Pezzola S, Di Matteo A, Scaloni F, Federici G . Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases. Cancer Res. 2009; 69(20):8025-34. DOI: 10.1158/0008-5472.CAN-09-1314. View

12.

Palumbo C, De Luca A, Rosato N, Forgione M, Rotili D, Caccuri A . c-Jun N-terminal kinase activation by nitrobenzoxadiazoles leads to late-stage autophagy inhibition. J Transl Med. 2016; 14:37. PMC: 4743117. DOI: 10.1186/s12967-016-0796-x. View

13.

Bradley J, Pober J . Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 2001; 20(44):6482-91. DOI: 10.1038/sj.onc.1204788. View

14.

Overman M, Petrofski J, Campbell P, De Marzo A, Nelson W . Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol. 2000; 17(6):1077-86. DOI: 10.3892/ijo.17.6.1077. View

15.

Lalle M, Camerini S, Cecchetti S, Finelli R, Sferra G, Muller J . The FAD-dependent glycerol-3-phosphate dehydrogenase of Giardia duodenalis: an unconventional enzyme that interacts with the g14-3-3 and it is a target of the antitumoral compound NBDHEX. Front Microbiol. 2015; 6:544. PMC: 4450592. DOI: 10.3389/fmicb.2015.00544. View

16.

Rappa G, Lorico A, Liu M, Kruh G, Cory A, CORY J . Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol. 1997; 54(6):649-55. DOI: 10.1016/s0006-2952(97)00210-4. View

17.

Phan L, Yeung S, Lee M . Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014; 11(1):1-19. PMC: 3969803. DOI: 10.7497/j.issn.2095-3941.2014.01.001. View

18.

Chung J, Park Y, Ye H, Wu H . All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002; 115(Pt 4):679-88. DOI: 10.1242/jcs.115.4.679. View

19.

Wu Y, Fan Y, Xue B, Luo L, Shen J, Zhang S . Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals. Oncogene. 2006; 25(42):5787-800. DOI: 10.1038/sj.onc.1209576. View

20.

Sau A, Filomeni G, Pezzola S, DAguanno S, Pellizzari Tregno F, Urbani A . Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Mol Biosyst. 2011; 8(4):994-1006. DOI: 10.1039/c1mb05295k. View